Cargando…
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
OBJECTIVE: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). METHODS: Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined...
Autores principales: | Li, Bowen, Wang, Jiu, Liu, Fangfang, Li, Rui, Hu, Weihong, Etcheverry, Amandine, Aubry, Marc, Mosser, Jean, Yin, Anan, Zhang, Xiang, Wu, Yuanming, Chen, Kun, He, Yalong, Wang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194959/ https://www.ncbi.nlm.nih.gov/pubmed/35712126 http://dx.doi.org/10.1155/2022/6345160 |
Ejemplares similares
-
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
por: Yin, An-An, et al.
Publicado: (2019) -
Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas
por: Yin, Anan, et al.
Publicado: (2021) -
A five‐CpG signature of microRNA methylation in non‐G‐CIMP glioblastoma
por: Kang, En‐Ming, et al.
Publicado: (2019) -
Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas
por: Yin, Anan, et al.
Publicado: (2017) -
DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)